Wordt geladen...
A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome
PURPOSE: Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects ∼9–50% of narcoleptics. Effects of 2-week SXB administration on apnea–hypopnea index (AHI), oxygen saturation (SaO(2)), and sleep architecture were...
Bewaard in:
| Hoofdauteurs: | , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer Berlin Heidelberg
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3098358/ https://ncbi.nlm.nih.gov/pubmed/20082240 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11325-009-0320-0 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|